温心颗粒治疗阳虚血瘀型不稳定型心绞痛的有效性和安全性:随机对照试验的研究方案
本研究为双盲、随机、安慰剂对照临床试验,计划纳入502例阳虚血瘀型不稳定型心绞痛患者,在常规药物治疗基础上分别加用温心颗粒或温心颗粒安慰剂,主要结局为主要不良心血管事件,治疗后1年评估,次要结局包括中医症状量表评分、西雅图心绞痛问卷和血栓弹力图,于基线及随机后4周、8周评估。
要点
- 温心颗粒治疗阳虚血瘀型不稳定型心绞痛的双盲随机安慰剂对照试验方案。
- 计划纳入502例,主要结局为主要不良心血管事件,1年时评估。
- 次要结局包括中医症状量表评分、西雅图心绞痛问卷和血栓弹力图。
核心结论
- 该试验旨在为温心颗粒治疗不稳定型心绞痛患者的获益与风险提供高质量数据。
研究设计与样本
- 双盲、随机、安慰剂对照临床试验,计划纳入502例参与者,随机分配至干预组和安慰剂组。
主要发现
- 干预组在常规药物治疗基础上加用温心颗粒,安慰剂组加用温心颗粒安慰剂。
- 主要结局为主要不良心血管事件,治疗1年后评估。
- 次要结局包括中医症状量表评分、西雅图心绞痛问卷和血栓弹力图,于基线(随机化前)及随机化后4周和8周评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Unstable angina pectoris (UAP) is the common type of coronary heart disease with the risk of developing into acute myocardial infarction (AMI). Currently, there are still numerous patients suffering from recurrent angina after revascularization or conventional medication due to the microvascular lesions, endothelial dysfunction, chronic inflammation, in-stent restenosis, and other factors. As an important part of China's medical and health care system, traditional Chinese medicine (TCM) has rich clinical experience in the treatment of UAP. According to the theory of TCM, Yang deficiency and blood stasis syndrome is a common type of UAP. Wen Xin decoction, as a type of Chinese herbal medicine, has been used in the clinic for years and shown great efficacy in the treatment of UAP with Yang deficiency and blood stasis syndrome. This study aims to evaluate the efficacy and safety of Wen Xin granular in patients with UAP. METHODS AND ANALYSIS: This is a double-blinded, randomized, placebo-controlled clinical trial. A total of 502 participants will be randomly allocated to the intervention group and the placebo group. Based on conventional medication, the intervention group will be treated with Wen Xin granular and the placebo group will be treated with Wen Xin granular placebo. The primary outcomes are major adverse cardiovascular events (MACE). Assessments will be performed 1 year after the treatment. The secondary outcomes include TCM symptom scale score, Seattle angina questionnaire, and thromboelastography. Assessments will be performed at baseline (before randomization) and 4 and 8 weeks after randomization. DISCUSSION: This trial will provide high-quality data on the benefits and risks of Wen Xin granular in patients with UAP. TRIAL REGISTRATION: ClinicalTrials.gov NCT04661709 . Registered on 30 November 2020.
引用
- Tian PP, Wu QJ, Li J, et al. Efficacy and safety of Chinese herbal medicine Wen Xin granules for the treatment of unstable angina pectoris with Yang deficiency and blood stasis syndrome: study protocol for a randomized controlled trial. Trials. 2021. PMID: 34774099. doi:10.1186/s13063-021-05771-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。